ArticleJournal of medicinal chemistry2019
Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues.
Article in Journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Recent progress in anti-Chikungunya virus drug discovery: Focus on the viral life cycle and direct-acting antivirals.Virologica Sinica · 2026Review
- Microwave-assisted nucleophilic fluorination: a facile approach to the synthesis of 6',6'-Frontiers in chemistry · 2026Article
- Design, Synthesis, and Antiviral Activity of 8‑Aza Fluoroneplanocin Derivatives Targeting SAH Hydrolase and Viral RdRp.ACS medicinal chemistry letters · 2025Article
- MAT2a and AHCY inhibition disrupts antioxidant metabolism and reduces glioblastoma cell survival.bioRxiv : the preprint server for biology · 2024Article
- Recent Advances in Molecular Mechanisms of Nucleoside Antivirals.Current issues in molecular biology · 2023Review
- An Isomer of Galidesivir That Potently Inhibits Influenza Viruses and Members of theACS medicinal chemistry letters · 2023Article
- Conserved coronavirus proteins as targets of broad-spectrum antivirals.Antiviral research · 2022Article
- The chemistry and biology of natural ribomimetics and related compounds.RSC chemical biology · 2022Review
- RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases.Journal of molecular structure · 2022Review
- Catalytic asymmetric synthesis of carbocyclic C-nucleosides.Communications chemistry · 2022Article
- Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-A perspective.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Antivirals against the Chikungunya Virus.Viruses · 2021Review
- Electron Donor-Acceptor Capacity of Selected Pharmaceuticals against COVID-19.Antioxidants (Basel, Switzerland) · 2021Article
- Human coronaviruses and therapeutic drug discovery.Infectious diseases of poverty · 2021Review
- RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic.European journal of medicinal chemistry · 2021Review
- Synthesis of novel seven-membered carbasugars and evaluation of their glycosidase inhibition potentials.RSC advances · 2021Article
- Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- The Dimroth Rearrangement in the Synthesis of Condensed Pyrimidines - Structural Analogs of Antiviral Compounds.Chemistry of heterocyclic compounds · 2021Article
- Functional and Pathological Roles of AHCY.Frontiers in cell and developmental biology · 2021Review
- Paving the way for small-molecule drug discovery.American journal of translational research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 6'-fluorinated aristeromycins were designed as dual-target antiviral compounds aimed at inhibiting both the viral RNA-dependent RNA polymerase (RdRp) and the host cell
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.